New frontiers in the medical management of gastrointestinal stromal tumours

Alessandro Mazzocca, Andrea Napolitano, Marianna Silletta, Mariella Spalato Ceruso, Daniele Santini, Giuseppe Tonini and Bruno Vincenzi

Abstract: The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardinal drug for patients with GISTs, novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatments with the approved TKI, or to treat subsets of GISTs driven by rarer molecular events. Here, we review the therapy of GISTs, with a particular focus on the newest drugs in advanced phases of clinical testing that might soon change the current therapeutic algorithm.

Keywords: avapritinib, BLU-285, DCC-2618, gastrointestinal stromal tumours, GIST, imatinib, ripretinib

Received: 31 December 2018; revised manuscript accepted: 13 March 2019.

Introduction
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms, with a global annual incidence of 10–15 cases per million.1–3 GISTs arise from the interstitial cells of Cajal4 primarily in the gastrointestinal (GI) tract, with the majority found in the stomach (60%),3 although extra-GI sites of origin are possible.5,6

Pathologic diagnosis is based on morphologic features and ancillary techniques, such as immunohistochemistry and molecular biology. Over 95% of GISTs are strongly and diffusely positive for CD117 (c-KIT).4 Several new immunohistochemistry (IHC) markers have been studied to improve the diagnostic accuracy, especially in KIT-negative GISTs. Among these, DOG1 (Discovered On Gist-1), a calcium-activated chloride channel, is a highly sensitive marker that can successfully identify most KIT-positive GISTs and up to one third of KIT-negative tumours.8

The most important prognostic factors determining the malignant potential of GISTs are tumour size (poor prognosis if >5 cm), mitotic count (expressed as the number of mitoses on a total area of 5 mm²) and tumour site.9,10 Recently, tumour rupture has been identified as an additional adverse prognostic factor.11 Molecular biology is an important tool because it may help to confirm the diagnosis and for its prognostic and predictive value in respect to disease sensitivity to targeted therapies. In most GISTs, activating mutations involving either KIT or platelet-derived growth factor receptor alpha (PDGFRα) genes, can be found.12 Approximately 60–85% of GISTs present KIT mutations. The most common affect exon 11, encoding for the juxtamembrane domain of the tyrosine kinase (TK) receptor. The main types of mutations are interstitial deletions, involving the initial portion of exon 11 (more often codons 557–559).13,14 In 9–20% of cases, KIT mutation occurs in exon 9, which encodes for the extracellular domain.15 This mutation is often associated with small bowel GISTs and to a greater malignant potential. Primary mutations of exons 13 and 17, encoding for KIT TK domains, have also been less frequently described.16 About 5–10% of GISTs presents activating mutations of PDGFRα, which are usually associated with localized gastric tumours. The D842V mutation, in exon 18,
which encodes for the TK domain, is the most frequently observed (65–75%;

GISTs represents one of the exceptional cases of solid tumours where the molecular biology is important to understand its medical therapy. Indeed, TK inhibitors (TKIs) are the standard therapy for KIT-mutated GISTs and will soon be the standard for PDGFRA-mutated ones, as well. In particular, the KIT inhibitor imatinib represented the first example of a TKI that radically changed the natural history of a solid tumour. Notably, the activity of TKIs largely depends on the specific mutations found in KIT and PDGFRA genes. With the upcoming approval of novel and more active TKIs, the molecular profile will become more and more important for the selection of the best therapy.

Approximately 10% of adult and 85% of paediatric GISTs do not present a mutation in either gene, and are therefore defined as ‘wildtype GISTs’. In these tumours, a number of genetic alterations have been described, including activating mutation of BRAF, inactivating mutations of NF1 or in genes encoding components of the succinate dehydrogenase (SDH) enzymatic complex, and gene fusions involving the kinase NTRK3. The spectrum of clinical behaviour of wildtype GISTs is variable, but slow progression is common, even in the metastatic setting.

Therapy of GISTs: current standards

Surgery

Localized setting. Surgery remains the mainstay of treatment for localized GISTs ≥2 cm. The aim is a complete gross resection, with negative microscopic margins and intact pseudocapsule, to avoid tumour rupture and intraperitoneal dissemination. Currently, there is no indication for routine lymphadenectomy. In small GISTs (<2 cm in the widest dimension), complete surgical resection is recommended in symptomatic patients, while an endoscopic surveillance at 6–12 months intervals should be considered.

Locally advanced and metastatic setting. Locally advanced primary GISTs deemed unresectable are currently treated with neoadjuvant imatinib, and surgery is offered to cases in which the medical therapy renders the GIST resectable. Surgery in metastatic or recurrent GISTs is more controversial and case selection is critical. It can be offered to patients whose disease is responding to imatinib or to those with limited focal progression, although impact on progression-free

Figure 1. Schematic representation of KIT and PDGFRA mutations found in GISTs. Relative sensitivities of primary and secondary KIT mutations to approved TKIs are shown in coloured boxes (green = sensitive; red = resistant). Note that KIT mutations in D816 are associated with resistance to all approved agents. GIST, gastrointestinal stromal tumours; PDGFRA, platelet-derived growth factor receptor α; TKI, tyrosine kinase inhibitor.
survival (PFS) and overall survival (OS) are unknown. Palliative surgery can also be considered in symptomatic patients.26

Imatinib

GISTs are known to be refractory to conventional chemotherapy and radiation. Since 2001, with the identification of targetable KIT activating mutations in GISTs,27 the introduction of TKIs has revolutionized the medical treatment of GISTs. Imatinib mesylate is a selective and potent drug inhibiting several TK receptors with a variable affinity, including KIT, the leukaemia-specific BCR-ABL chimera, and PDGFRs.28,29

Adjuvant setting. Even though complete gross resection is possible in 85% of patients with primary localized GISTs, at least 50% of them develop tumour recurrence. The postoperative approach is based on an assessment of the overall risk of recurrence.24,30 Over time, prognostic factors have been identified to assess the risk of recurrence after surgery, and used to define risk categories.9,31–35 Currently, the most widely used prognostication tool is the classification proposed by Joensuu and colleagues which considers tumour size, mitotic count, tumour site and tumour rupture as risk factors.36 In 2008, for the first time a recurrence-free survival (RFS) and OS benefit was shown from 1-year adjuvant imatinib at a dose of 400 mg/day in high-risk patients. This study also showed that KIT exon 11 mutations responded better to a standard dose of imatinib than KIT exon 9 mutations.37 The following phase III trial led to imatinib approval in the adjuvant setting.38 The Scandinavian-German SSG XVIII study, published in 2012, showed that postoperative imatinib administered for 3 years could improve both RFS and OS compared with 1 year in high-risk patients.39

In 2008, the first time a recurrence-free survival (RFS) and OS benefit was shown from 1-year adjuvant imatinib at a dose of 400 mg/day in high-risk patients. This study also showed that KIT exon 11 mutations responded better to a standard dose of imatinib than KIT exon 9 mutations.37 The following phase III trial led to imatinib approval in the adjuvant setting.38 The Scandinavian-German SSG XVIII study, published in 2012, showed that postoperative imatinib administered for 3 years could improve both RFS and OS compared with 1 year in high-risk patients.39

The American PERSIST-5, a phase II, single-arm study, recently completed, is investigating the efficacy of 5 years of adjuvant imatinib in preventing relapse in high-risk patients harbouring sensitive mutations (ClinicalTrials.gov identifier: NCT00867113). Similarly, SSG XXII is a new intergroup phase III randomized study, comparing 3 years versus 5 years of adjuvant imatinib treatment in high-risk GISTs (ClinicalTrials.gov identifier: NCT02413736).

Currently, both European Society for Medical Oncology and National Comprehensive Cancer Network (NCCN) guidelines recommend 3 years of adjuvant treatment with imatinib in patients with a significant risk of relapse. Patients with PDGFRA D842V-mutated GISTs should not be treated with imatinib, due to its known resistance. Since no data suggest a benefit of the standard dose of imatinib in KIT exon 9-mutated GISTs and given the proven efficacy of a daily dose of 800 mg/day of imatinib in metastatic GISTS, in clinical practice the higher dose is preferred also in the adjuvant setting. The use of adjuvant imatinib in wildtype SDH-negative tumours is still controversial, while in NF1-related GISTs it should be avoided.

Neoadjuvant setting. In patients with large or poorly localized tumours requiring extensive surgery with significant morbidity or sacrifice of large amount of normal tissue, preoperative imatinib should be considered, given its good safety profile,40–44 although no conclusive evidence from large phase III clinical trials is available. The most appropriate duration of preoperative imatinib is still controversial, with a preferred interval between 6 and 12 months before surgery, as the best response is usually expected in this frame.45

First-line metastatic disease. Imatinib represents the first-line standard treatment for unresectable, recurrent or metastatic disease. The standard dose of imatinib is 400 mg daily.46,47 Importantly, an early interruption of imatinib is associated with a high risk of progression even in patients with a complete response, therefore the treatment should be continued until significant toxicity or disease progression.48–50

The assessment of tumour genotype is necessary, since it predicts different sensitivities to imatinib. KIT exon 11 mutations are associated with a better response to imatinib (400 mg daily), whereas KIT exon 9 mutations are less sensitive and may require a higher dose (800 mg daily), in order to achieve similar therapeutic results.51–54 The PDGFRA exon 18 D842V mutation is resistant to imatinib, while other mutations of the same gene may be associated with variable sensitivity.17 Wildtype GISTs are also thought to be less sensitive to imatinib.

Mechanisms of resistance to imatinib and disease progression. Primary resistance to imatinib (observed in 10% of patients) is defined as disease progression within 6 months of therapy. The most common causes are represented by PDGFRA D842V or KIT exon 9 (under standard
dose) mutations or wildtype subtypes. Secondary or acquired resistance, observed in initially responding or stable GISTs, is defined as disease progression after 6 months of therapy. The major mechanism is represented by the acquisition of secondary KIT mutations, as in KIT ATP-binding pocket (exons 13 and 14), which evade imatinib binding, and in KIT activation loops (exons 17 and 18), which enhance constitutive KIT activation.

In advanced GISTs progressing during imatinib treatment, patient noncompliance and potential drug interactions with concomitant medications altering plasmatic levels of imatinib should be assessed. Moreover, responding tumours may show increase in size during early treatment with imatinib as a consequence of necrosis, myxoid degeneration or intra-tumoural haemorrhage, mimicking disease progression. Notably, the Choi criteria, which combine morphologic tumour volume response and changes in lesions density, show a higher sensitivity and specificity in the evaluation of treatment response compared with the widely used morphologic response evaluation criteria in solid tumors (RECIST).

In patients with confirmed disease progression, additional treatment options may be considered before switching to a second-line therapy. In patients with limited progression, resistant lesions may be treated with surgical resection. Another option to consider is dosage escalation of imatinib (to 800 mg per day), as a clinical benefit can be observed in about 30–35% of patients.

**Second-line and third-line TKIs**

**Sunitinib.** Sunitinib malate is an oral multi-targeted TKI, with activity against KIT, PDGFR, vascular endothelial growth factor receptor (VEGFR), RET and FMS-like TK receptor 3 (FLT-3). It represents the standard second-line treatment for imatinib-resistant or imatinib-intolerant patients based on a multicentre phase III trial showing a significant increase in the median time to progression compared with placebo. An open-label phase II trial has shown efficacy of a continuous daily dose of sunitinib 37.5 mg, with a clinical benefit rate of 53%, a median PFS of 34 weeks and a median OS of 107 weeks. Although the recommended schedule is 50 mg per day for 4 weeks followed by a 2 week rest, the continuous use of 37.5 mg daily has been approved in the United States and European Union as an alternative option in selected cases. The range of sunitinib-related adverse events is greater than those for imatinib, due to its wider spectrum of target inhibition. The most common side effects reported are fatigue, diarrhoea, hand-foot syndrome, hypertension and skin discoloration. As with imatinib, GIST genotypes relate to sunitinib responses: patients with primary KIT exon 9 mutations or wildtype tumours (for KIT/PDGFRA mutations) show a higher clinical benefit in terms of PFS and OS. Moreover, regarding secondary resistance, KIT mutations involving the ATP-binding pocket (exon 13 and 14) are thought to be more sensitive to sunitinib than those involving the activation loop domain (exon 17 and 18).

**Regorafenib.** Regorafenib is an oral TKI active against several kinases involved in oncogenesis (KIT, PDGFR, RET, RAF1 and BRAF), in the regulation of angiogenesis (VEGFR1-3 and TIE2) and the tumour microenvironment [PDGFRs fibroblast growth factor receptors (FGFR)]. It represents the standard third-line treatment in patients with advanced GISTs after a randomized phase III trial which revealed a significant improvement in PFS compared with placebo. The recommended dose of regorafenib is 160 mg taken once daily for 3 weeks followed by 1 week off therapy. The most common adverse events observed in patients receiving regorafenib are hypertension, hand-foot skin reaction and diarrhoea.

**Beyond the approved lines**

Despite the clear successes of TKIs in the treatment for advanced and metastatic GISTs, acquired resistance to all approved agents eventually occurs. In patients progressing after imatinib, sunitinib and regorafenib, enrolment in clinical trials should be considered.

**Imatinib rechallenge**

The reintroduction of previously tolerated and effective TKI therapy can be considered for palliation of symptoms in addition to best supportive care. The RIGHT trial, a randomized, double-blind, placebo-controlled, phase III study, showed efficacy and safety of imatinib rechallenge in patients after failure of at least imatinib and sunitinib. Similarly, imatinib rechallenge after progression to sunitinib and regorafenib is associated with a potential clinical benefit.
**Sorafenib**

Sorafenib is a pleotropic multi-TKI that has been used for advanced GISTs refractory to conventional treatments. Retrospective\(^{67,68}\) as well as small prospective\(^{69}\) experiences showed objective responses in about 5–10% of the patients and disease stabilization in more than half of them in the third-line and forth-line settings. Importantly, the activity of sorafenib on secondary KIT mutations usually associated with resistance to imatinib was also shown in preclinical models.\(^{70}\)

**Nilotinib**

Nilotinib inhibits the TK activity of ABL1/BCR-ABL1, KIT, and PDGFRs. Nilotinib did not show superiority against imatinib in the first-line setting in a phase III clinical trial,\(^{71}\) nor against best supportive care in GISTs following prior imatinib and sunitinib failure.\(^{72}\) Nevertheless, a number of patients showed a significant response with different side-effect profiles from imatinib. Thus, nilotinib might still merit attention as an alternative to imatinib in patients with advanced GISTs who are intolerant to imatinib.

**Pazopanib**

Pazopanib is a multi-TKI that inhibits KIT, PDGFRs, and has particularly potent activity of VEGFRs, with proved activity in soft tissue sarcomas. A randomized phase II trial of pazopanib in GISTs in the third-line setting after treatment with imatinib and sunitinib showed disease control at 4 months in more than 40% of the patients treated with pazopanib.\(^{73}\)

**Novel therapies for advanced and metastatic GISTs**

So far, the unique and most important breakthrough in the medical treatment of advanced and metastatic GISTs has been the successful use of imatinib to target pathogenic KIT mutants. Other TKIs, whether approved or not, showed efficacy in a more limited number of patients, and with a shorter average clinical benefit.

Novel molecules currently in late-stage clinical trials have the potential to be the next breakthroughs in the therapy of KIT and even more so, PDGFRα-mutated GISTs. Among these, particularly interesting data have been presented for ripretinib (formerly known as DCC-2618) and avapritinib (formerly known as BLU-285; Table 1). A list of selected ongoing phase II and III clinical trials is shown in Table 2.

**Ripretinib [DCC-2618]**

Ripretinib is a switch-control type II inhibitor of KIT, which arrests KIT in an inactive state, inhibiting the full spectrum of the mutations known to be present in patients with GISTs in exons 9, 11, 13, 14, 17, and 18, as well as an inhibitor of PDGFRα carrying exon 18 mutations, including the D842V mutation.\(^{76}\)

The most recently updated results from the phase I clinical trial of ripretinib were presented at the CTOS Annual Meeting in 2018 in Rome, Italy.

A total of 178 patients with KIT-mutated GISTs have been treated so far. In the second-line setting, ripretinib showed an overall response rate (ORR) and disease control rate (DCR) at 3 months by RECIST respectively of 18% and 79%, with a median PFS of 42 weeks. In the third-line setting, ORR and DCR were respectively of 24% and 83%, with a PFS of 40 weeks. In the ≥fourth-line setting, ORR, DCR were respectively of 9% and 66%, with a PFS of 24 weeks. Ripretinib showed good tolerability, which allowed for prolonged treatment duration in second-line and third-line settings.

Treatment emergent adverse events (TEAEs) associated with ripretinib were generally of grade 1 and 2. The most common grade 3 TEAEs was clinically asymptomatic lipase increase (11%). Out of 178 patients treated, 24 (14%) experienced dose reduction due to TEAEs and 19 (11%) experienced treatment discontinuations due to TEAEs.\(^{74}\)

Ripretinib is being tested in a pivotal, randomized, placebo-controlled phase III study, INVICTUS (ClinicalTrials.gov identifier: NCT03353753), in the ≥fourth-line population. In December 2018, a second phase III study, INTRIGUE (ClinicalTrials.gov identifier: NCT03673501), was announced in second-line patients with GISTs after imatinib failure against the standard therapy, sunitinib.

**Avapritinib [BLU-285]**

Avapritinib is a highly selective and potent a type I KIT/PDGFRα inhibitor that binds to the active protein kinase conformation, with biochemical activity against a wide range of primary and secondary mutations in the nanomolar range and confirmed activity
in vitro in KIT-mutant cell lines and in an in vivo subcutaneous allograft mouse model.\(^7\)

The updated results of the NAVIGATOR phase I trial were recently presented at the CTOS Annual Meeting in 2018. A total of four different populations of patients with GISTs were included in this trial: (1) GISTs in second-line; (2) GISTs in third/fourth-line regorafenib-naïve; (3) GISTs in fourth or more advanced lines; (4) PDGFRA D842V-mutated GISTs.

In the second-line, the reported ORR was 25%, but data on this cohort are still limited. In patients in third/fourth-line regorafenib-naïve setting, avapritinib was associated with an ORR of 26%.

### Table 1. ORR of ripretinib and avapritinib compared with other approved drugs.

| Drug name      | Line of treatment | ORR  | Ref                                |
|----------------|-------------------|------|------------------------------------|
| Sunitinib      | 2                 | 7%   | Demetri and colleagues\(^6\)        |
| Regorafenib    | 3                 | 5%   | Demetri and colleagues\(^4\)        |
| Ripretinib     | 2                 | 18%  | George and colleagues\(^7\)         |
| Ripretinib     | 3                 | 24%  | George and colleagues\(^7\)         |
| Ripretinib     | \(\geq 4\)        | 9%   | George and colleagues\(^7\)         |
| Avapritinib    | 3/4 regorafenib-naïve | 26% | Heinrich and colleagues\(^5\)      |
| Avapritinib    | \(\geq 4\)        | 20%  | Heinrich and colleagues\(^5\)      |

ORR, overall response rate.

### Table 2. Selected list of phase II and phase III clinical trials.

| Drug name      | Population                        | Line of treatment                        | Phase | ClinicalTrials.gov identifier |
|----------------|-----------------------------------|-----------------------------------------|-------|-------------------------------|
| Avapritinib    | KIT/PDGFRA-mutated                | 3rd/4th regorafenib-naïve               | III   | NCT03465722                   |
| Ripretinib     | KIT/PDGFRA-mutated                | 2nd line                                | III   | NCT03673501                   |
| Masitinib      | KIT-positive [immunohistochemistry] imatinib-resistant/progressive | \(\geq 2\) line | III | NCT01694277 |
| Crenolanib     | PDGFRA D842V-mutated              | any                                     | III   | NCT02847429                   |
| Ponatinib      | KIT/PDGFRA-mutated                | 2nd line (cohort A); after all approved lines (cohort B) | II    | NCT03171389                   |
| Cabozantinib   | KIT/PDGFRA-mutated                | 3rd line                                | II    | NCT02216578                   |
| Regorafenib    | KIT/PDGFRA wildtype GIST          | 1st line                                | II    | NCT02638766                   |
| Temozolamide   | SDH-mutant/deficient GIST         | any                                     | II    | NCT03556384                   |
| Nivolumab ± ipilimumab | Imatinib-resistant/progressive     | \(\geq 2\) line | II | NCT02880020 |
| Epadocast + Pembrolizumab | Imatinib-resistant/progressive | 2nd to 5th line | II | NCT03291054 |

GIST, gastrointestinal stromal tumour.
and a median duration of response (mDOR) of about 10 months. In the ≥fourth-line setting, ORR was 20% with a mDOR of over 7 months. In these patients, the rare PDGFRA V654A and T670I mutations were associated with lower response rates, providing a strong rationale for genotype-selected therapy. In patients with GISTs with a PDGFRA D842V mutation, avapritinib caused tumour shrinkage in 98% of the cases, with an ORR of 84% (including 9% of complete radiological responses), an unprecedented result in a disease known to be resistant to imatinib.

Most TEAEs were grade 1 and 2, with manageable on-target toxicity. Nausea, vomiting, and peri-orbital oedema were the most common reported toxicities. Grade 3 anaemia was relatively frequent (25%). About 9% of the patients discontinued due to TEAEs.

The phase III VOYAGER trial (ClinicalTrials.gov identifier: NCT03465722) is currently enrolling patients with GISTs who are known to have a KIT or PDGFRA mutation previously treated with imatinib and one or two other TKIs. Patients will be randomized to receive avapritinib versus regorafenib. The primary endpoint of this trial is PFS, with ORR, OS and quality-of-life measures as secondary endpoints.

Currently, no other clinical trials with avapritinib in other settings are planned or enrolling.

Masitinib
Masitinib is a highly selective oral TKI with comparable activity to imatinib against wildtype and mutant KIT (exons 9 and 11). After promising phase I data, masitinib activity was evaluated in a phase II trial in advanced imatinib-resistant GISTs against sunitinib. Masitinib met its noncomparative primary PFS endpoint, with a median PFS of 3.7 months. A phase III trial investigating masitinib in imatinib-resistant/intolerant patients is currently ongoing (ClinicalTrials.gov identifier: NCT01694277).

Crenolanib
Crenolanib is a potent inhibitor of imatinib-resistant PDGFRA kinases associated with GISTs, including the PDGFRA D842V mutation that drives a subset of GISTs. Clinical activity was observed in PDGFRA-mutated GISTs in a dose-escalating phase II trial, therefore a phase III was initiated specifically in patients with GISTs with D842V-mutated PDGFRA (ClinicalTrials.gov identifier: NCT02847429).

Ponatinib
Ponatinib is a TKI approved for imatinib-resistant BCR-ABL leukaemia, and has shown in vitro activity against a number of primary and secondary KIT mutations also in GIST models. A phase II trial is currently evaluating its activity in patients with GISTs after prior failure or intolerability of imatinib (ClinicalTrials.gov identifier: NCT03171389).

Cabozantinib
Cabozantinib is a multi-TKI approved for the treatment of medullary thyroid cancer and as a second-line treatment for renal cell carcinoma. In preclinical models, cabozantinib showed antitumor activity in GISTs through inhibition of tumour growth, proliferation, and angiogenesis, in both imatinib-sensitive and imatinib-resistant models. The clinical validity of cabozantinib is being explored in patients who have previously progressed on imatinib and sunitinib (ClinicalTrials.gov identifier: NCT02216578).

Other targeted therapies for rare mutations
A single case has been described of a patient carrying a GIST with BRAF mutations treated with the BRAF inhibitor dabrafenib, and it showed good disease control.

Very recently, gene fusions involving the kinase NTRK3 have been identified in KIT/PDGFRα/BRAF-mutation negative, SDH-proficient GISTs. Although rare, this subtype might greatly benefit from targeted therapy with tropomyosin receptor kinase (TRK) inhibitors.

Targeted therapies for GISTs with inactivating mutations in NF1 or SDH components appear to be further away in the development. SDHB mutations have been associated with a response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma, and based on this a phase II trial is ongoing testing temozolomide in SDH-deficient GISTs (ClinicalTrials.gov identifier: NCT03556384).

Immunotherapy
Few trials are currently exploring a potential role for checkpoint inhibitors in TKIs-resistant GISTs.
(see Table 2), based on the presence of a diverse range of infiltrating inflammatory cells in GISTs. Alternative forms of immunotherapy, such as the use of specific anti-KIT antibodies and of chimeric antigen receptor T-cells, are also at early stages of development.

Discussion

A number of novel TKIs will soon be available for the treatment of advanced and metastatic GISTs after imatinib failure. Understanding the mechanisms of resistance to approved and novel TKIs will likely determine a genotype-driven therapeutic choice.

However, progression under imatinib is associated with the emergence of subclones harbouring multiple secondary KIT mutations.

The simultaneous evaluation of most KIT secondary mutations through re-biopsy of imatinib-progressive cases appears impractical unless in the presence of oligo-progressive disease. The early identification of these mutations is an emerging medical need. Circulating tumour DNA sequencing could in theory act as a surrogate source to provide a comprehensive record of all secondary KIT mutations simultaneously present in a single patient, but it might not be sensitive enough for cases without large tumour burden.

So-called ‘wildtype’ GISTs represent a small but significant fraction of GISTs, and recent efforts have identified additional drivers, such as BRAF and SDHB mutations and the NTRK3 fusion gene. This effort has to continue to identify the yet unknown driver events in the remaining cases, in order to increase the likelihood of targeted therapies for this population. Accrual of these patients in specific clinical trials should be encouraged by clinicians. Nevertheless, the clinical approval of novel therapies for patients with wildtype GISTs still appears relatively distant in time.

Conclusions

The current algorithm for the medical management of KIT-driven GISTs has imatinib as the standard therapy in the neoadjuvant and adjuvant settings, as well as in the metastatic setting as a first-line treatment. A number of TKIs in clinical trials, in particular ripretinib and avapritinib, appear to be more effective than imatinib in unresectable or metastatic PDGFRA-driven GISTs. In this subset of patients, we therefore expect the fast approval of novel compounds.

In KIT-driven GISTs, imatinib is the standard therapy, and will likely continue to be for a long time. Instead, given the available results, ripretinib and avapritinib will probably soon change the second-line and third-line treatment after imatinib failure. A potential treatment algorithm is proposed in Figure 2. Importantly, caution is needed as these data derive from early-phase clinical trials, whereas sunitinib and regorafenib have shown their efficacy in a phase III trial. Examples of a
promising drug in phase I/II trials that did not confirm the results in larger trials are abundant, most notably the recent failure of olaratumab in soft tissue sarcomas.88

Nevertheless, as our understanding of the molecular biology of GISTs develops, novel rationally designed therapies are expected to cover also wildtype GISTs which currently represent a subset with very limited therapeutic options.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**ORCID iD**

Andrea Napolitano https://orcid.org/0000-00-02-7509-1555

**References**

1. Rubin BP, Heinrich MC and Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369: 1731–1741.

2. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007; 7: 230.

3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer 2005; 103: 821–829.

4. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259–1269.

5. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109–1118.

6. Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577–585.

7. Hornick JL and Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007; 38: 679–687.

8. Miettinen M, Wang ZF and Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009; 33: 1401–1408.

9. Miettinen M and Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70–83.

10. Edge SB and Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–1474.

11. Takahashi T, Nakajima K, Nishitani A, et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 2007; 12: 369–374.

12. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology 2006; 48: 83–96.

13. Corless CL, Fletcher JA and Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813–3825.

14. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23: 6190–6198.

15. Kato N, Kato S and Ueno H. Hemangiopericytoma: characteristic features observed by magnetic resonance imaging and angiography. J Dermatol 1990; 17: 701–706.

16. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000; 157: 1091–1095.

17. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357–5364.

18. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRα wild-type gastrointestinal stromal tumours. J Clin Pathol 2009; 62: 613–616.
19. Pantaleo MA, Astolfi A, Urbini M, et al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/ PDGFRα wild-type GIST. *Eur J Hum Genet* 2014; 22: 32–39.

20. Miettinen M, Fersch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. *Am J Surg Pathol* 2006; 30: 90–96.

21. Brenca M, Rossi S, Polano M, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. *J Pathol* 2016; 238: 543–549.

22. Shi E, Chmielecki J, Tang CM, et al. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors. *J Transl Med* 2016; 14: 339.

23. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. *Ann Surg Oncol* 2000; 7: 705–712.

24. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw* 2010; 8(Suppl. 2): S1–S41; quiz S42–S44.

25. Sepe PS and Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. *Nat Rev Gastroenterol Hepatol* 2009; 6: 363–371.

26. Ford SJ and Gronchi A. Indications for surgery in advanced/metastatic GIST. *Eur J Cancer* 2016; 63: 154–167.

27. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med* 2001; 344: 1052–1056.

28. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat Med* 1996; 2: 561–566.

29. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood* 2000; 96: 925–932.

30. McCarter MD, Antonescu CR, Ballman KV, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. *J Am Coll Surg* 2012; 215: 53–59; discussion 59–60.

31. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 2000; 231: 51–58.

32. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. *Hum Pathol* 2002; 33: 459–465.

33. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. *Lancet Oncol* 2009; 10: 1045–1052.

34. Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011; 35: 1646–1656.

35. Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. *J Gastrointest Surg* 2014; 18: 2123–2129.

36. Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. *Lancet Oncol* 2012; 13: 265–274.

37. DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. *Ann Surg* 2013; 258: 422–429.

38. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009; 373: 1097–1104.

39. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. *JAMA* 2012; 307: 1265–1272.

40. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6655. *J Surg Oncol* 2009; 99: 42–47.

41. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. *Ann Surg Oncol* 2012; 19: 1074–1080.
42. Hohenberger P, Langer C, Wendtner CM, et al. Neoadjuvant treatment of locally advanced GIST: results of APOLLO, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors. J Clin Oncol 2012; 30(Suppl.): abstr 10031.

43. Kurokawa Y, Yang HK, Cho H, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 2017; 117: 25–32.

44. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2009; 35: 739–745.

45. Tirumani SH, Shinagare AB, Jagannathan JP, et al. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumours to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol 2014; 40: 420–428.

46. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127–1134.

47. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626–632.

48. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107–1113.

49. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942–949.

50. Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013; 24: 1087–1093.

51. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360–5367.

52. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342–4349.

53. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093–1103.

54. Gastrointestinal Stromal Tumor Meta-Analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247–1253.

55. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumours. J Clin Oncol 2006; 24: 4764–4774.

56. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

57. Choi H, Charmsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753–1759.

58. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–2331.

59. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347–352.

60. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751–1757.

61. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329–1338.

62. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal...
stromal tumour after imatinib failure. *Eur J Cancer* 2009; 45: 1959–1968.

63. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008; 26: 5352–5359.

64. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381: 295–302.

65. Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2013; 14: 1175–1182.

66. Vincenzi B, Nannini M, Badalamenti G, et al. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumours following progression with imatinib, sunitinib and regorafenib. *Ther Adv Med Oncol* 2018; 10:1758835918794623.

67. Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis. *Eur J Cancer* 2013; 49: 1027–1031.

68. Rutkowski P, Jagielska B, Andrzejuk J, et al. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumours (GIST). *Contemp Oncol (Pozn)* 2017; 21: 285–289.

69. Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumours who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumours study group. *Invest New Drugs* 2012; 30: 2377–2383.

70. Heinrich MC, Marino-Enriquez A, Pressnell A, et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. *Mol Cancer Ther* 2012; 11: 1770–1780.

71. Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. *Lancet Oncol* 2015; 16: 550–560.

72. Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumours resistant to or intolerant of imatinib and sunitinib. *Ann Oncol* 2012; 23: 1680–1687.

73. Mir O, Crozet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. *Lancet Oncol* 2016; 17: 632–641.

74. George S, Heinrich MC, Chi P, et al. Initial Results of Phase 1 Study of DCC-2618, a Broad-spectrum KIT and PDGFRA Inhibitor, in Patients (pts) with Gastrointestinal Stromal Tumor (GIST) by Numer of Prior Regimen. *CTOS*. 2018.

75. Heinrich M, von Mehren M, Jones RL, et al. Avapritinib is highly active and well-tolerated in patients with advanced GIST driven by a diverse variety of oncogenic mutations in KIT and PDGFRA. *CTOS*. 2018.

76. Smith BD, Hood MM, Wise SC, et al. DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models. *Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; Cancer Res* 2015; 75(Suppl. 15): abstract nr 2690.

77. Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. *Sci Transl Med* 2017; 9(414): eaa01690.

78. Adenis A, Blay JY, Bui-Nguyen B, et al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. *Ann Oncol* 2014; 25: 1762–1769.

79. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res* 2012; 18: 4375–4384.

80. Garner AP, Gozgit JM, Anjum R, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clin Cancer Res* 2014; 20: 5745–5755.

81. Gebreyohannes YK, Schoffski P, Van Looy T, et al. Cabozantinib is active against human gastrointestinal stromal tumor xenografts carrying different KIT mutations. *Mol Cancer Ther* 2016; 15: 2845–2852.
82. Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. *Oncotarget* 2013; 4: 310–315.

83. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018; 378: 731–739.

84. Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. *Int J Cancer* 2014; 135: 2711–2720.

85. Tan Y, Trent JC, Wilky BA, et al. Current status of immunotherapy for gastrointestinal stromal tumor. *Cancer Gene Ther* 2017; 24: 130–133.

86. Xu H, Chen L, Shao Y, et al. Clinical application of circulating tumor DNA in the genetic analysis of patients with advanced GIST. *Mol Cancer Ther* 2018; 17: 290–296.

87. Namlos HM, Boye K, Mishkin SJ, et al. Noninvasive detection of ctDNA reveals intratumor heterogeneity and is associated with tumor burden in gastrointestinal stromal tumor. *Mol Cancer Ther* 2018; 17: 2473–2480.

88. Napolitano A and Vincenzi B. PDGFRalpha inhibition in soft-tissue sarcomas: have we gotten it all wrong? *EBioMedicine* 2019; 40: 37–38.